Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Stanley S, Katz, Arie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801192/
https://www.ncbi.nlm.nih.gov/pubmed/27042132
http://dx.doi.org/10.2147/DMSO.S65588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801192/
https://www.ncbi.nlm.nih.gov/pubmed/27042132
http://dx.doi.org/10.2147/DMSO.S65588

Ejemplares similares